Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus. A 52-week randomised, double-blind, active- and placebo-controlled trial

Trial Profile

Efficacy and Safety of Oral Semaglutide versus Liraglutide and versus Placebo in Subjects with Type 2 Diabetes Mellitus. A 52-week randomised, double-blind, active- and placebo-controlled trial

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2018

At a glance

  • Drugs Semaglutide (Primary) ; Liraglutide; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms PIONEER 4
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 17 Apr 2018 This trial has been completed in Croatia (End date: 2018-03-30).
    • 14 Apr 2018 This trial has been completed in Croatia (End date: 2018-03-30) .
    • 27 Mar 2018 This trial has been completed in Germany.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top